Alcon (NYSE: ALC) reported Q1 EPS of $0.49, $0.04 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.92 billion.

"The first quarter was a solid start to the year, with healthy sales, a return to 2019 core margin levels and the substantial completion of our separation activities. Strong commercial execution of our new product launches continues to drive market share gains despite the continued impacts of COVID-19," said David Endicott, Chief Executive Officer.

Mr. Endicott continued, "I want to thank the hundreds of Alcon associates who have spent the past two years working to complete our separation and establish our independence as the global leader in eye care. Their extraordinary work is allowing us to devote more time to accelerating innovation and driving above-market sales growth. Our recent success validates our continued investment in a robust product pipeline that will meet the future needs of eye care professionals and their patients."

GUIDANCE:

Alcon sees FY2021 EPS of $1.85-$1.95, versus the consensus of $1.92. Alcon sees FY2021 revenue of $7.8-8 billion, versus the consensus of $7.87 billion.

For earnings history and earnings-related data on Alcon (ALC) click here.